多系统萎缩、进行性核上性麻痹MRI、TCS的临床研究
|
摘要
目的：探讨多系统萎缩（MSA）、进行性核上性麻痹（PSP）的临床表现特征。
方法：对临床确诊的36例MSA、7例PSP，性别、年龄匹配的43例特发性PD作为对照组，进行详细的病史询问，体格检查。主要包括患者的发病年龄、首发症状、疾病进展过程出现的症状、病程、确定诊断时间，服用抗帕金森病药物的疗效，以及患者的文化程度、生活环境、家族史、脑血管病病史、特殊用药史、一氧化碳中毒史、毒物接触史等情况。
结果：MSA-P组、MSA-C组、PSP组和PD组起病年龄分别为62.548.12岁、59.026.12岁、68.387.05岁，62.67.8岁；MSA-C发病年龄较PSP组显著低（P＜0.05），其余各组间发病年龄无显著差异。MSA-P组、MSA-C组和PSP组震颤发生率（分别为48.0%、36.4%、42.9%）均较PD组（88.4%）低（P＜0.05），MSA-C组强直症状发生率（90.1%）较PD组（86.0%）显著高（P＜0.05）。MSA-P组Romberg征阳性率（32.0%）较PD组（9.3%）显著高（P＜0.05），MSA-C组指鼻试验阳性率（63.6%）、Romberg征阳性率（63.6%）较PD组（23.3%，9.3%）显著高（P＜0.05）。MSA-C组体位性低血压发生率（36.4%）较PD组（4.7%）显著高（P＜0.05）。MSA-P痴呆、凝视麻痹、锥体束征/腱反射亢进发生率（分别为16.0%、12.0%、16.0%）较PD组（4.7%、0、0）显著高（P＜0.05），MSA-C组构音障碍、凝视麻痹、体位性低血压、锥体束征/腱反射亢进发生率（分别为63.6%、18.2%、36.4%、36.4%）较PD组（分别为23.3%、0、4.7%、0）显著高（P＜0.05）；PSP组跌倒、扫视/追踪减慢、痴呆、凝视麻痹、锥体束征/腱反射亢进发生率（分别为85.7%、57.1%、42.9%、71.4%、28.6%）较PD组（16.3%、11.6%、4.7%、0、0）发生率显著高（P＜0.05）。
结论：MSA和PSP有各自独特的临床特征，相同症状、体征在各组发生率与PD组存在一定差异，有一定鉴别诊断价值。
目的：探讨多系统萎缩（MSA）、进行性核上性麻痹（PSP）的MRI形态学上的特点，进行定量分析，为早期诊断和鉴别诊断提供客观依据。
方法：经临床确诊的29例MSA、7例PSP为病例组，性别、年龄配对的36例帕金森病（PD）患者为病例对照组，性别、年龄配对的36例健康人为正常对照组，采用Philips Achieva1.5T超导型全身磁共振成像仪及标准Sense-head头线圈行常规MRI检查。主要观察指标：（1）T_2WI信号改变：①桥脑十字征（桥脑基底部可见十字样高信号）；②小脑中脚高信号；③壳核裂隙征（壳核外侧缘裂隙样高信号）。（2）T1WI图像上，①大脑萎缩；②小脑萎缩；③脑干（中脑、桥脑、延髓）萎缩。在图形工作站上应用软件View Forum4.1进行数据测量：在T1WI正中矢状位上测量桥脑面积、中脑面积并计算桥脑面积与中脑面积比值；在T1WI轴位上测量双侧小脑中脚宽度。
结果：29例MSA中有5例（17.2%）出现十字征，4例（13.8%）出现裂隙征；其中MSA-P组小脑、延髓萎缩发生率（分别为33.3%、14.3%），MSA-C组的颞叶、小脑、中脑、桥脑、延髓萎缩发生率（分别为37.5%、62.5%、37.5%、37.5%、37.5%）较PD组（4.7%、7.0%、4.7%、4.7%、0）和对照组（4.7%、2.3%、0、0、0）显著高（P＜0.05），PSP组颞叶萎缩、中脑、桥脑萎缩发生率（分别为42.9%、85.7%、28.6%）较PD组（4.7%、4.7%、4.7%）和对照组（4.7%、0、0）显著高（P＜0.05）。MSA-C组的十字征、MCP高信号征发生率（50.0%、50.0%）较PD组（0、0）和对照组（0、0）显著高（P＜0.05）。7例PSP中有5例（71.4%）出现蜂鸟征，PSP组蜂鸟征发生率（71.4%）较PD组（0）和对照组（0）显著高（P＜0.05）。21例MSA-P的中脑、桥脑面积和小脑中脚宽度（130.951.9mm~2、414.493.5mm~2、12.02.5mm）和8例MSA-C的小脑中脚宽度（12.82.9mm）较PD组（149.325.3mm~2、502.664.8mm~2、15.81.4mm）和健康对照组（150.617.2mm~2、503.844.9mm~2、16.11.0mm）显著性减少（P＜0.05）。PSP组中脑、桥脑面积分别是97.434.2mm~2、458.642.5mm~2，其中，中脑面积与PD组和健康对照组显著性减小（P＜0.05）。
结论：常规MRI形态学特点，定量分析有助于MSA、PSP及IPD的诊断及鉴别诊断，对MSA的分型具有一定的参考价值。
目的：探讨多系统萎缩经颅超声（TCS）特点，为诊断及鉴别诊断提供客观依据。
方法：经临床确诊的22例MSA作为病例组，性别、年龄配对的22例帕金森病（PD）患者为病例对照组。仪器采用GE vivid7，M3S探头，探头频率：2.0～2.5MHz，动态范围：45～55dB，深度：15～17mm。探头置于颞窗部位紧贴皮肤，平行于耳眶线（耳尖与眼角连线）。主要观察指标：（1）黑质回声强度进行半定量分级；（2）双侧黑质强同声总面积/中脑总面积比值。
结果：22例行TCS检查MSA患者1例图像效果不佳（排除），剩余21例MSA患者中，7例（33.3％）表现黑质强回声，22例PD有2例TCS图像效果不佳（排除），剩余20例PD患者，13例（65.0％）表现为黑质强回声。MSA组黑质强回声发生率较PD组显著低（χ2=4.11，P=0.043）。MSA组7例黑质回声≥Ⅲ级，面积0.16～0.97cm~2，PD组13例黑质回声≥Ⅲ级，面积为0.23～1.3cm~2，对MSA组和PD组黑质强回声≥III级面积测量值和S/M比值进行比较，差异无统计学意义（P>0.05）。Wilcoxon检验表明，MSA组和PD组黑质强回声阳性的各分级分布有显著差异（Z=-3.12，P>0.05）。
结论：MSA患者TCS黑质强回声发生率较PD组显著低，TCS检查有助于MSA和PD鉴别诊断。
Objective: To explore the clinical features in multiple system atrophy and progressivesupranuclear palsy.
Methods: We choose36patients with MSA,7patients with PSP diagnosed in thesecond affiliated hospital of Soochow University, Detailed history and physicalexamination of were collected, mainly includes the onset age, onset symptoms, symptomsduring progress of the disease, course of disease, diagnosis time, effect of anti-Parkinson'sdisease drug, and education, living environment, family history of cerebral vascular disease,special medication history, carbon monoxide poisoning history and poison contact history.
Results: The onset age of MSA-P group, MSA-C group, PSP group and PD groupwere62.548.12years、59.026.12years、68.387.05years，62.67.8years respectively.The onset age of MSA-C group was significantly lower (P <0.05) compared with PDgroup. The incidence of tremor in MSA-P group, MSA-C group and PSP group (48.0%,36.4%,42.9%respectively) was significantly lower than that in PD group (88.4%)(P <0.05), The incidence of rigidity in MSA-C group (90.1%) was higher than PD group(86.0%)(P<0.05). The positive rate of Romberg sign in group MSA-P (32%) was higherthan PD group (9.3%)(P <0.05).The positive rate of nasal test (63.6%) and Romberg sign(63.6%) in MSA-C group were higher than PD group (23.3%,9.3%respectively)(P <0.05). The incidence of orthostatic hypotension (36.4%) in MSA-C group was higher thanPD group (4.7%)(P<0.05). The incidence of cognitive impairment, palsy, pyramidal signs/tendon reflexes hyperfunction in MSA-P group (16%,12%,16%respectively) werehigher than group PD (4.7%,0,0respectively)(P<0.05), The incidence of dysarthria, gazepalsy, orthostatic hypotension, extrapyramidal syndrome/tendon reflexes hyperfunction in MSA-C group (63.6%,18.2%,36.4%,36.4%respectively) were higher than PD group(23.3%,0,4.7%,0respectively)(P <0.05); The incidence of falls, saccade/tracking down,cognitive impairment, gaze palsy, pyramidal signs/tendon reflexes hyperfunction in PSPgroup (85.7%,57.1%,42.9%,71.4%,28.6%respectively) were higher than PD group(16.3%,11.6%,4.7%,0,0respectively)(P <0.05).
Conclusion: MSA and PSP have their own unique clinical features, the incidence ofthe same symptoms/signs were different in each group, may be helpful in differentialdiagnosis with PD group
Objective: To explore and quantitatively analyze morphology features in multiplesystem atrophy and progressive supranuclear palsy, provided objective evidence fordiagnosis and differential diagnosis of these diseases.
Methods:29cases of MSA,7cases of PSP, gender, age matched36cases ofParkinson's disease (PD) as case group, and gender, age matched36healthy objects ascontrols, using Philips Achieva1.5T superconducting whole-body magnetic resonanceimaging instrument and standard Sense-head head coil conventional MRI examination.Main measures:(1) T_2WI signal changes: the pontine cross sign (the basal portion of thepons visible cross high signal);②middle cerebellar peduncle high signal;③putaminalslit syndrome (putamen outer margin fissured high signal).(2) T1WI images, the brainatrophy;②cerebellar atrophy;③brainstem (medulla oblongata, midbrain, pons)atrophy. The datas were measured by of software View Forum4.1in the graphicworkstation: measuring area of pons and midbrain in the T1WI sagittal; measuring bilateralcerebellar peduncle width in the T1WI axis.
Results:5cases(17.2%) of MSA show cross sign,4cases (13.8%) show slicksyndrome;The incidence of cerebellum atrophy, medulla atrophy in MSA-P group(33.3%,14.3%), and temporal lobe atrophy, cerebellum atrophy, midbrain atrophy, pons atrophy,medulla atrophy in MSA-C group (37.5%,.62.5%,37.5%,37.5%,37.5%respectively) was significantly higher than PD group (4.7%,7%,4.7%,4.7%,0) and control group (4.7%,2.3%,0,0,0)(P <0.05), The incidence of temporal lobe atrophy, midbrain atrophy,pontine atrophy in PSP group (42.9%,85.7%,28.6%, respectively) were significantlyhigher than PD group (4.7%,4.7%,4.7%) and control group (4.7%,0,0)(P <0.05). Theincidence of crusade, high signal on MCP in MSA-C group (50%,50%) was significantlyhigher than PD group (0,0) and control group (0,0)(P <0.05).5cases (71.4%) of PSPshow hummingbird sign, the incidence of hummingbird sign in PSP group(71.4%) wassignificantly higher than PD group (0) and control group (0)(P <0.05). The midbrain area,pons area and middle cerebellar peduncle width in the21cases of MSA-P (130.9±51.9mm~2,414.4±93.5mm~2,12.0±2.5mm) and cerebellar peduncle width in MSA-C (12.8±2.9mm) decreased significantly than PD group (149.325.3mm~2、502.664.8mm~2、15.81.4mm) and control group (150.617.2mm~2、503.844.9mm~2、16.11.0mm)(P<0.05). The midbrain area of PSP (97.434.2mm~2) was significantly reduced than PDgroup and healthy control group (P <0.05).
Conclusion: Quantitative analysis of morphological features by conventional MRI,contributed to the diagnosis and differential diagnosis of MSA, PSP and IPD. and hadcertain value to the MSA subtype.
Objective: To explore the TCS characteristics of multiple system atrophy, provideobjective evidence for diagnosis and differential diagnosis.
Methods:21cases of MSA, gender, age-matched21cases of Parkinson's disease (PD)patients as case group. The instrument adopts GE vivid7, M3S probe, probe frequency:2~2.5MHz, dynamic range:45~55dB,15~17mm depth. The probe is arranged in thetemporal window close to the skin, the orbital line parallel to the ear (tip of ear and eyeline). Main measures:(1) Semiquantitatively graded substantia nigra echogenicity;(2)Theratio: area of bilateral substantia nigra hypoechogenicity/total area of midbrain.
Results: TCS was performed in22cases of MSA and22cases of PD,1patients withMSA and2patients with PD were excluded for the image ineffective,7cases (33.3%) of the remaining21MSA showed nigral hyperechogenicity,13cases (65%) of the remaining20PD cases showed the substantia nigra hyperechogenicity. Chi-square analysis showedthat the incidence of substantia nigra hyperechogenicity in MSA group was significantlyhigher than PD group (χ2=4.11, P=0.043).7cases of MSA (33.3%) in substantia nigrahyperechogenicity≥grade Ⅲ, the area was0.16~0.97cm~2.12cases (54.2%) of PD insubstantia nigra hyperechogenicity≥grade Ⅲ, area0.23~1.3cm~2, there were nosignificant difference of the area in substantia nigra hyperechogenicity≥Ⅲ and theratio of S/M between MSA and PD group (P<0.05). The distribution of grade in positivesubstantia nigra echogenic was significant different between MSA and PD (Z=-3.12, P <0.05).
Conclusion: The incidence of substantia nigra hyperechogenicity in MSA wassignificantly lower than in PD.TCS was helpful for the differential diagnosis of MSA andPD.
方法：对临床确诊的36例MSA、7例PSP，性别、年龄匹配的43例特发性PD作为对照组，进行详细的病史询问，体格检查。主要包括患者的发病年龄、首发症状、疾病进展过程出现的症状、病程、确定诊断时间，服用抗帕金森病药物的疗效，以及患者的文化程度、生活环境、家族史、脑血管病病史、特殊用药史、一氧化碳中毒史、毒物接触史等情况。
结果：MSA-P组、MSA-C组、PSP组和PD组起病年龄分别为62.548.12岁、59.026.12岁、68.387.05岁，62.67.8岁；MSA-C发病年龄较PSP组显著低（P＜0.05），其余各组间发病年龄无显著差异。MSA-P组、MSA-C组和PSP组震颤发生率（分别为48.0%、36.4%、42.9%）均较PD组（88.4%）低（P＜0.05），MSA-C组强直症状发生率（90.1%）较PD组（86.0%）显著高（P＜0.05）。MSA-P组Romberg征阳性率（32.0%）较PD组（9.3%）显著高（P＜0.05），MSA-C组指鼻试验阳性率（63.6%）、Romberg征阳性率（63.6%）较PD组（23.3%，9.3%）显著高（P＜0.05）。MSA-C组体位性低血压发生率（36.4%）较PD组（4.7%）显著高（P＜0.05）。MSA-P痴呆、凝视麻痹、锥体束征/腱反射亢进发生率（分别为16.0%、12.0%、16.0%）较PD组（4.7%、0、0）显著高（P＜0.05），MSA-C组构音障碍、凝视麻痹、体位性低血压、锥体束征/腱反射亢进发生率（分别为63.6%、18.2%、36.4%、36.4%）较PD组（分别为23.3%、0、4.7%、0）显著高（P＜0.05）；PSP组跌倒、扫视/追踪减慢、痴呆、凝视麻痹、锥体束征/腱反射亢进发生率（分别为85.7%、57.1%、42.9%、71.4%、28.6%）较PD组（16.3%、11.6%、4.7%、0、0）发生率显著高（P＜0.05）。
结论：MSA和PSP有各自独特的临床特征，相同症状、体征在各组发生率与PD组存在一定差异，有一定鉴别诊断价值。
目的：探讨多系统萎缩（MSA）、进行性核上性麻痹（PSP）的MRI形态学上的特点，进行定量分析，为早期诊断和鉴别诊断提供客观依据。
方法：经临床确诊的29例MSA、7例PSP为病例组，性别、年龄配对的36例帕金森病（PD）患者为病例对照组，性别、年龄配对的36例健康人为正常对照组，采用Philips Achieva1.5T超导型全身磁共振成像仪及标准Sense-head头线圈行常规MRI检查。主要观察指标：（1）T_2WI信号改变：①桥脑十字征（桥脑基底部可见十字样高信号）；②小脑中脚高信号；③壳核裂隙征（壳核外侧缘裂隙样高信号）。（2）T1WI图像上，①大脑萎缩；②小脑萎缩；③脑干（中脑、桥脑、延髓）萎缩。在图形工作站上应用软件View Forum4.1进行数据测量：在T1WI正中矢状位上测量桥脑面积、中脑面积并计算桥脑面积与中脑面积比值；在T1WI轴位上测量双侧小脑中脚宽度。
结果：29例MSA中有5例（17.2%）出现十字征，4例（13.8%）出现裂隙征；其中MSA-P组小脑、延髓萎缩发生率（分别为33.3%、14.3%），MSA-C组的颞叶、小脑、中脑、桥脑、延髓萎缩发生率（分别为37.5%、62.5%、37.5%、37.5%、37.5%）较PD组（4.7%、7.0%、4.7%、4.7%、0）和对照组（4.7%、2.3%、0、0、0）显著高（P＜0.05），PSP组颞叶萎缩、中脑、桥脑萎缩发生率（分别为42.9%、85.7%、28.6%）较PD组（4.7%、4.7%、4.7%）和对照组（4.7%、0、0）显著高（P＜0.05）。MSA-C组的十字征、MCP高信号征发生率（50.0%、50.0%）较PD组（0、0）和对照组（0、0）显著高（P＜0.05）。7例PSP中有5例（71.4%）出现蜂鸟征，PSP组蜂鸟征发生率（71.4%）较PD组（0）和对照组（0）显著高（P＜0.05）。21例MSA-P的中脑、桥脑面积和小脑中脚宽度（130.951.9mm~2、414.493.5mm~2、12.02.5mm）和8例MSA-C的小脑中脚宽度（12.82.9mm）较PD组（149.325.3mm~2、502.664.8mm~2、15.81.4mm）和健康对照组（150.617.2mm~2、503.844.9mm~2、16.11.0mm）显著性减少（P＜0.05）。PSP组中脑、桥脑面积分别是97.434.2mm~2、458.642.5mm~2，其中，中脑面积与PD组和健康对照组显著性减小（P＜0.05）。
结论：常规MRI形态学特点，定量分析有助于MSA、PSP及IPD的诊断及鉴别诊断，对MSA的分型具有一定的参考价值。
目的：探讨多系统萎缩经颅超声（TCS）特点，为诊断及鉴别诊断提供客观依据。
方法：经临床确诊的22例MSA作为病例组，性别、年龄配对的22例帕金森病（PD）患者为病例对照组。仪器采用GE vivid7，M3S探头，探头频率：2.0～2.5MHz，动态范围：45～55dB，深度：15～17mm。探头置于颞窗部位紧贴皮肤，平行于耳眶线（耳尖与眼角连线）。主要观察指标：（1）黑质回声强度进行半定量分级；（2）双侧黑质强同声总面积/中脑总面积比值。
结果：22例行TCS检查MSA患者1例图像效果不佳（排除），剩余21例MSA患者中，7例（33.3％）表现黑质强回声，22例PD有2例TCS图像效果不佳（排除），剩余20例PD患者，13例（65.0％）表现为黑质强回声。MSA组黑质强回声发生率较PD组显著低（χ2=4.11，P=0.043）。MSA组7例黑质回声≥Ⅲ级，面积0.16～0.97cm~2，PD组13例黑质回声≥Ⅲ级，面积为0.23～1.3cm~2，对MSA组和PD组黑质强回声≥III级面积测量值和S/M比值进行比较，差异无统计学意义（P>0.05）。Wilcoxon检验表明，MSA组和PD组黑质强回声阳性的各分级分布有显著差异（Z=-3.12，P>0.05）。
结论：MSA患者TCS黑质强回声发生率较PD组显著低，TCS检查有助于MSA和PD鉴别诊断。
Objective: To explore the clinical features in multiple system atrophy and progressivesupranuclear palsy.
Methods: We choose36patients with MSA,7patients with PSP diagnosed in thesecond affiliated hospital of Soochow University, Detailed history and physicalexamination of were collected, mainly includes the onset age, onset symptoms, symptomsduring progress of the disease, course of disease, diagnosis time, effect of anti-Parkinson'sdisease drug, and education, living environment, family history of cerebral vascular disease,special medication history, carbon monoxide poisoning history and poison contact history.
Results: The onset age of MSA-P group, MSA-C group, PSP group and PD groupwere62.548.12years、59.026.12years、68.387.05years，62.67.8years respectively.The onset age of MSA-C group was significantly lower (P <0.05) compared with PDgroup. The incidence of tremor in MSA-P group, MSA-C group and PSP group (48.0%,36.4%,42.9%respectively) was significantly lower than that in PD group (88.4%)(P <0.05), The incidence of rigidity in MSA-C group (90.1%) was higher than PD group(86.0%)(P<0.05). The positive rate of Romberg sign in group MSA-P (32%) was higherthan PD group (9.3%)(P <0.05).The positive rate of nasal test (63.6%) and Romberg sign(63.6%) in MSA-C group were higher than PD group (23.3%,9.3%respectively)(P <0.05). The incidence of orthostatic hypotension (36.4%) in MSA-C group was higher thanPD group (4.7%)(P<0.05). The incidence of cognitive impairment, palsy, pyramidal signs/tendon reflexes hyperfunction in MSA-P group (16%,12%,16%respectively) werehigher than group PD (4.7%,0,0respectively)(P<0.05), The incidence of dysarthria, gazepalsy, orthostatic hypotension, extrapyramidal syndrome/tendon reflexes hyperfunction in MSA-C group (63.6%,18.2%,36.4%,36.4%respectively) were higher than PD group(23.3%,0,4.7%,0respectively)(P <0.05); The incidence of falls, saccade/tracking down,cognitive impairment, gaze palsy, pyramidal signs/tendon reflexes hyperfunction in PSPgroup (85.7%,57.1%,42.9%,71.4%,28.6%respectively) were higher than PD group(16.3%,11.6%,4.7%,0,0respectively)(P <0.05).
Conclusion: MSA and PSP have their own unique clinical features, the incidence ofthe same symptoms/signs were different in each group, may be helpful in differentialdiagnosis with PD group
Objective: To explore and quantitatively analyze morphology features in multiplesystem atrophy and progressive supranuclear palsy, provided objective evidence fordiagnosis and differential diagnosis of these diseases.
Methods:29cases of MSA,7cases of PSP, gender, age matched36cases ofParkinson's disease (PD) as case group, and gender, age matched36healthy objects ascontrols, using Philips Achieva1.5T superconducting whole-body magnetic resonanceimaging instrument and standard Sense-head head coil conventional MRI examination.Main measures:(1) T_2WI signal changes: the pontine cross sign (the basal portion of thepons visible cross high signal);②middle cerebellar peduncle high signal;③putaminalslit syndrome (putamen outer margin fissured high signal).(2) T1WI images, the brainatrophy;②cerebellar atrophy;③brainstem (medulla oblongata, midbrain, pons)atrophy. The datas were measured by of software View Forum4.1in the graphicworkstation: measuring area of pons and midbrain in the T1WI sagittal; measuring bilateralcerebellar peduncle width in the T1WI axis.
Results:5cases(17.2%) of MSA show cross sign,4cases (13.8%) show slicksyndrome;The incidence of cerebellum atrophy, medulla atrophy in MSA-P group(33.3%,14.3%), and temporal lobe atrophy, cerebellum atrophy, midbrain atrophy, pons atrophy,medulla atrophy in MSA-C group (37.5%,.62.5%,37.5%,37.5%,37.5%respectively) was significantly higher than PD group (4.7%,7%,4.7%,4.7%,0) and control group (4.7%,2.3%,0,0,0)(P <0.05), The incidence of temporal lobe atrophy, midbrain atrophy,pontine atrophy in PSP group (42.9%,85.7%,28.6%, respectively) were significantlyhigher than PD group (4.7%,4.7%,4.7%) and control group (4.7%,0,0)(P <0.05). Theincidence of crusade, high signal on MCP in MSA-C group (50%,50%) was significantlyhigher than PD group (0,0) and control group (0,0)(P <0.05).5cases (71.4%) of PSPshow hummingbird sign, the incidence of hummingbird sign in PSP group(71.4%) wassignificantly higher than PD group (0) and control group (0)(P <0.05). The midbrain area,pons area and middle cerebellar peduncle width in the21cases of MSA-P (130.9±51.9mm~2,414.4±93.5mm~2,12.0±2.5mm) and cerebellar peduncle width in MSA-C (12.8±2.9mm) decreased significantly than PD group (149.325.3mm~2、502.664.8mm~2、15.81.4mm) and control group (150.617.2mm~2、503.844.9mm~2、16.11.0mm)(P<0.05). The midbrain area of PSP (97.434.2mm~2) was significantly reduced than PDgroup and healthy control group (P <0.05).
Conclusion: Quantitative analysis of morphological features by conventional MRI,contributed to the diagnosis and differential diagnosis of MSA, PSP and IPD. and hadcertain value to the MSA subtype.
Objective: To explore the TCS characteristics of multiple system atrophy, provideobjective evidence for diagnosis and differential diagnosis.
Methods:21cases of MSA, gender, age-matched21cases of Parkinson's disease (PD)patients as case group. The instrument adopts GE vivid7, M3S probe, probe frequency:2~2.5MHz, dynamic range:45~55dB,15~17mm depth. The probe is arranged in thetemporal window close to the skin, the orbital line parallel to the ear (tip of ear and eyeline). Main measures:(1) Semiquantitatively graded substantia nigra echogenicity;(2)Theratio: area of bilateral substantia nigra hypoechogenicity/total area of midbrain.
Results: TCS was performed in22cases of MSA and22cases of PD,1patients withMSA and2patients with PD were excluded for the image ineffective,7cases (33.3%) of the remaining21MSA showed nigral hyperechogenicity,13cases (65%) of the remaining20PD cases showed the substantia nigra hyperechogenicity. Chi-square analysis showedthat the incidence of substantia nigra hyperechogenicity in MSA group was significantlyhigher than PD group (χ2=4.11, P=0.043).7cases of MSA (33.3%) in substantia nigrahyperechogenicity≥grade Ⅲ, the area was0.16~0.97cm~2.12cases (54.2%) of PD insubstantia nigra hyperechogenicity≥grade Ⅲ, area0.23~1.3cm~2, there were nosignificant difference of the area in substantia nigra hyperechogenicity≥Ⅲ and theratio of S/M between MSA and PD group (P<0.05). The distribution of grade in positivesubstantia nigra echogenic was significant different between MSA and PD (Z=-3.12, P <0.05).
Conclusion: The incidence of substantia nigra hyperechogenicity in MSA wassignificantly lower than in PD.TCS was helpful for the differential diagnosis of MSA andPD.
引文
[1] Mitra K, Gangopadhaya PK,Das SK. Parkinsonism plus syndrome--a review[J].Neurol India,2003,51(2):183-8.
[2] Lang AE,Lozano AM. Parkinson's disease. First of two parts[J]. N Engl J Med,1998,339(15):1044-53.
[3] Zhang ZX, Roman GC, Hong Z, et al. Parkinson's disease in China: prevalence inBeijing, Xian, and Shanghai[J]. Lancet,2005,365(9459):595-7.
[4]徐仁,吴成斯,易娟, et al.帕金森叠加综合征[J].国外医学（老年医学分册）,2007,28(6):4.
[5] Tison F, Yekhlef F, Chrysostome V, et al. Prevalence of multiple system atrophy[J].Lancet,2000,355(9202):495-6.
[6] Bjornsdottir A, Gudmundsson G, Blondal H, et al. Incidence and prevalence ofmultiple system atrophy: a nationwide study in Iceland[J]. J Neurol NeurosurgPsychiatry,2013,84(2):136-40.
[7] Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinicalphenotypes in pathologically proven progressive supranuclear palsy: Richardson'ssyndrome and PSP-parkinsonism[J]. Brain,2005,128(Pt6):1247-58.
[8] Barsottini OG, Felicio AC, Aquino CC, et al. Progressive supranuclear palsy: newconcepts[J]. Arq Neuropsiquiatr,2010,68(6):938-46.
[9] Schrag A, Ben-Shlomo Y,Quinn NP. Prevalence of progressive supranuclear palsyand multiple system atrophy: a cross-sectional study[J]. Lancet,1999,354(9192):1771-5.
[10] Nath U, Ben-Shlomo Y, Thomson RG, et al. The prevalence of progressivesupranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK[J]. Brain,2001,124(Pt7):1438-49.
[11] Seppi K. MRI for the differential diagnosis of neurodegenerative parkinsonism inclinical practice[J]. Parkinsonism Relat Disord,2007,13Suppl3: S400-5.
[12] Behnke S, Berg D, Naumann M, et al. Differentiation of Parkinson's disease andatypical parkinsonian syndromes by transcranial ultrasound[J]. J Neurol NeurosurgPsychiatry,2005,76(3):423-5.
[13] Berg D. Transcranial sonography in movement disorders. Conclusions[J]. Int RevNeurobiol,2010,90:287-9.
[1] Lantos PL. The definition of multiple system atrophy: a review of recentdevelopments[J]. J Neuropathol Exp Neurol,1998,57(12):1099-111.
[2] Gilman S, Wenning GK, Low PA, et al. Second consensus statement on thediagnosis of multiple system atrophy[J]. Neurology,2008,71(9):670-6.
[3] Iodice V, Lipp A, Ahlskog JE, et al. Autopsy confirmed multiple system atrophycases: Mayo experience and role of autonomic function tests[J]. J NeurolNeurosurg Psychiatry,2012,83(4):453-9.
[4] Stefanova N, Bucke P, Duerr S, et al. Multiple system atrophy: an update[J]. LancetNeurol,2009,8(12):1172-8.
[5] Williams DR,Lees AJ. How do patients with parkinsonism present? Aclinicopathological study[J]. Intern Med J,2009,39(1):7-12.
[6] Wenning GK, Tison F, Ben Shlomo Y, et al. Multiple system atrophy: a review of203pathologically proven cases[J]. Mov Disord,1997,12(2):133-47.
[7] Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple systematrophy: an analysis of230Japanese patients[J]. Brain,2002,125(Pt5):1070-83.
[8] Yabe I, Soma H, Takei A, et al. MSA-C is the predominant clinical phenotype ofMSA in Japan: analysis of142patients with probable MSA[J]. J Neurol Sci,2006,249(2):115-21.
[9] Ito T, Sakakibara R, Yasuda K, et al. Incomplete emptying and urinary retention inmultiple-system atrophy: when does it occur and how do we manage it?[J]. MovDisord,2006,21(6):816-23.
[10] Wenning GK, Granata R, Krismer F, et al. Orthostatic hypotension is differentiallyassociated with the cerebellar versus the parkinsonian variant of multiple systematrophy: a comparative study[J]. Cerebellum,2012,11(1):223-6.
[11] Wenning GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatichypotension and urinary incontinence in patients with postmortem confirmedparkinsonian syndromes: a clinicopathological study[J]. J Neurol NeurosurgPsychiatry,1999,67(5):620-3.
[12] Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement ofthe striatonigral and olivopontocerebellar systems in multiple system atrophy:clinicopathological correlations[J]. Brain,2004,127(Pt12):2657-71.
[13] Spaccavento S, Del Prete M, Loverre A, et al. Multiple system atrophy with earlycognitive deficits: A case report[J]. Neurocase,2012,
[14] Steele JC, Richardson JC,Olszewski J. Progressive Supranuclear Palsy. AHeterogeneous Degeneration Involving the Brain Stem, Basal Ganglia andCerebellum with Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia andDementia[J]. Arch Neurol,1964,10:333-59.
[15] Barsottini OG, Felicio AC, Aquino CC, et al. Progressive supranuclear palsy: newconcepts[J]. Arq Neuropsiquiatr,2010,68(6):938-46.
[16]詹霞,王远臣,隋秀梅.进行性核上性麻痹3例并文献复习[J].疑难病杂志,2006,5(4):2.
[17] Lubarsky M,Juncos JL. Progressive supranuclear palsy: a current review[J].Neurologist,2008,14(2):79-88.
[18] Dubois B, Slachevsky A, Pillon B, et al."Applause sign" helps to discriminate PSPfrom FTD and PD[J]. Neurology,2005,64(12):2132-3.
[19] Kertesz A,McMonagle P. Behavior and cognition in corticobasal degeneration andprogressive supranuclear palsy[J]. J Neurol Sci,2010,289(1-2):138-43.
[20] Soliveri P, Monza D, Paridi D, et al. Neuropsychological follow up in patients withParkinson's disease, striatonigral degeneration-type multisystem atrophy, andprogressive supranuclear palsy[J]. J Neurol Neurosurg Psychiatry,2000,69(3):313-8.
[1] Konagaya M, Sakai M, Matsuoka Y, et al. Pathological correlate of the slitlikechanges on MRI at the putaminal margin in multiple system atrophy[J]. J Neurol,1999,246(2):142-3.
[2] Matsusue E, Fujii S, Kanasaki Y, et al. Putaminal lesion in multiple system atrophy:postmortem MR-pathological correlations[J]. Neuroradiology,2008,50(7):559-67.
[3] Watanabe H, Ito M, Fukatsu H, et al. Putaminal magnetic resonance imagingfeatures at various magnetic field strengths in multiple system atrophy[J]. MovDisord,2010,25(12):1916-23.
[4] Tha KK, Terae S, Tsukahara A, et al. Hyperintense putaminal rim at1.5T:prevalence in normal subjects and distinguishing features from multiple systematrophy[J]. BMC Neurol,2012,12:39.
[5] Savoiardo M, Strada L, Girotti F, et al. Olivopontocerebellar atrophy: MR diagnosisand relationship to multisystem atrophy[J]. Radiology,1990,174(3Pt1):693-6.
[6] Yokoyama T, Hasegawa K, Horiuchi E, et al. Multiple system atrophy (MSA) withmassive macrophage infiltration in the ponto-cerebellar afferent system[J].Neuropathology,2007,27(4):375-7.
[7] Cordato NJ, Duggins AJ, Halliday GM, et al. Clinical deficits correlate withregional cerebral atrophy in progressive supranuclear palsy[J]. Brain,2005,128(Pt6):1259-66.
[8] Schofield EC, Hodges JR, Macdonald V, et al. Cortical atrophy differentiatesRichardson's syndrome from the parkinsonian form of progressive supranuclearpalsy[J]. Mov Disord,2011,26(2):256-63.
[9] Morelli M, Arabia G, Novellino F, et al. MRI measurements predict PSP inunclassifiable parkinsonisms: a cohort study[J]. Neurology,2011,77(11):1042-7.
[10] Morelli M, Arabia G, Salsone M, et al. Accuracy of magnetic resonanceparkinsonism index for differentiation of progressive supranuclear palsy fromprobable or possible Parkinson disease[J]. Mov Disord,2011,26(3):527-33.
[1] Berg D. Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease:yes[J]. J Neural Transm,2011,118(4):613-9.
[2] Bartova P, Skoloudik D, Bar M, et al. Transcranial sonography in movementdisorders[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2008,152(2):251-8.
[3] Berg D. In vivo detection of iron and neuromelanin by transcranial sonography--anew approach for early detection of substantia nigra damage[J]. J Neural Transm,2006,113(6):775-80.
[4] Walter U. Transcranial sonography in brain disorders with trace metal accumulation[J].Int Rev Neurobiol,2010,90:166-78.
[5] Behnke S, Berg D, Naumann M, et al. Differentiation of Parkinson's disease andatypical parkinsonian syndromes by transcranial ultrasound[J]. J Neurol NeurosurgPsychiatry,2005,76(3):423-5.
[6] Gaenslen A, Unmuth B, Godau J, et al. The specificity and sensitivity of transcranialultrasound in the differential diagnosis of Parkinson's disease: a prospective blindedstudy[J]. Lancet Neurol,2008,7(5):417-24.
[7] Walter U, Niehaus L, Probst T, et al. Brain parenchyma sonography discriminatesParkinson's disease and atypical parkinsonian syndromes[J]. Neurology,2003,60(1):74-7.
[8] Walter U, Dressler D, Wolters A, et al. Sonographic discrimination of corticobasaldegeneration vs progressive supranuclear palsy[J]. Neurology,2004,63(3):504-9.
[9] Walter U, Dressler D, Lindemann C, et al. Transcranial sonography findings inwelding-related Parkinsonism in comparison to Parkinson's disease[J]. Mov Disord,2008,23(1):141-5.
[1] Graham JG,Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in acase of multiple system atrophy[J]. J Neurol Neurosurg Psychiatry,1969,32(1):28-34.
[2] Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosisof multiple system atrophy[J]. Neurology,2008,71(9):670-6.
[3] Steele JC, Richardson JC,Olszewski J. Progressive Supranuclear Palsy. AHeterogeneous Degeneration Involving the Brain Stem, Basal Ganglia andCerebellum with Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia andDementia[J]. Arch Neurol,1964,10:333-59.
[4] Schrag A, Ben-Shlomo Y,Quinn NP. Prevalence of progressive supranuclear palsy andmultiple system atrophy: a cross-sectional study[J]. Lancet,1999,354(9192):1771-5.
[5] Barsottini OG, Felicio AC, Aquino CC, et al. Progressive supranuclear palsy: newconcepts[J]. Arq Neuropsiquiatr,2010,68(6):938-46.
[6] Ito S, Shirai W,Hattori T. Putaminal hyperintensity on T1-weighted MR imaging inpatients with the Parkinson variant of multiple system atrophy[J]. AJNR Am JNeuroradiol,2009,30(4):689-92.
[7] Matsusue E, Fujii S, Kanasaki Y, et al. Putaminal lesion in multiple system atrophy:postmortem MR-pathological correlations[J]. Neuroradiology,2008,50(7):559-67.
[8] Tha KK, Terae S, Tsukahara A, et al. Hyperintense putaminal rim at1.5T: prevalencein normal subjects and distinguishing features from multiple system atrophy[J]. BMCNeurol,2012,12:39.
[9] Sakurai K, Yamawaki T, Okita K, et al. Utility of the fluid-attenuated inversionrecovery sequence in detecting a hyperintense putaminal rim in multiple systematrophy-parkinsonism: a preliminary study[J]. Eur Neurol,2011,66(1):42-6.
[10] Watanabe H, Ito M, Fukatsu H, et al. Putaminal magnetic resonance imaging featuresat various magnetic field strengths in multiple system atrophy[J]. Mov Disord,2010,25(12):1916-23.
[11] Savoiardo M, Strada L, Girotti F, et al. Olivopontocerebellar atrophy: MR diagnosisand relationship to multisystem atrophy[J]. Radiology,1990,174(3Pt1):693-6.
[12] Massey LA, Micallef C, Paviour DC, et al. Conventional magnetic resonance imagingin confirmed progressive supranuclear palsy and multiple system atrophy[J]. MovDisord,2012,
[13] Ngai S, Tang YM, Du L, et al. Hyperintensity of the middle cerebellar peduncles onfluid-attenuated inversion recovery imaging: variation with age and implications forthe diagnosis of multiple system atrophy[J]. AJNR Am J Neuroradiol,2006,27(10):2146-8.
[14] Okamoto K, Tokiguchi S, Furusawa T, et al. MR features of diseases involvingbilateral middle cerebellar peduncles[J]. AJNR Am J Neuroradiol,2003,24(10):1946-54.
[15] Kataoka H, Tonomura Y, Taoka T, et al. Signal changes of superior cerebellarpeduncle on fluid-attenuated inversion recovery in progressive supranuclear palsy[J].Parkinsonism Relat Disord,2008,14(1):63-5.
[16] Righini A, Antonini A, De Notaris R, et al. MR imaging of the superior profile of themidbrain: differential diagnosis between progressive supranuclear palsy andParkinson disease[J]. AJNR Am J Neuroradiol,2004,25(6):927-32.
[17] Kato N, Arai K,Hattori T. Study of the rostral midbrain atrophy in progressivesupranuclear palsy[J]. J Neurol Sci,2003,210(1-2):57-60.
[18] Adachi M, Kawanami T, Ohshima H, et al. Morning glory sign: a particular MRfinding in progressive supranuclear palsy[J]. Magn Reson Med Sci,2004,3(3):125-32.
[19] Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation ofprogressive supranuclear palsy from Parkinson disease and the Parkinson variant ofmultiple system atrophy[J]. Radiology,2008,246(1):214-21.
[20] Gama RL, Tavora DF, Bomfim RC, et al. Morphometry MRI in the differentialdiagnosis of parkinsonian syndromes[J]. Arq Neuropsiquiatr,2010,68(3):333-8.
[21] Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsoniansyndromes with routine MRI[J]. Neurology,2000,54(3):697-702.
[22] Oba H, Yagishita A, Terada H, et al. New and reliable MRI diagnosis for progressivesupranuclear palsy[J]. Neurology,2005,64(12):2050-5.
[23] Morelli M, Arabia G, Salsone M, et al. Accuracy of magnetic resonance parkinsonismindex for differentiation of progressive supranuclear palsy from probable or possibleParkinson disease[J]. Mov Disord,2011,26(3):527-33.
[24] Schulz JB, Skalej M, Wedekind D, et al. Magnetic resonance imaging-basedvolumetry differentiates idiopathic Parkinson's syndrome from multiple systematrophy and progressive supranuclear palsy[J]. Ann Neurol,1999,45(1):65-74.
[25] Specht K, Minnerop M, Muller-Hubenthal J, et al. Voxel-based analysis ofmultiple-system atrophy of cerebellar type: complementary results by combiningvoxel-based morphometry and voxel-based relaxometry[J]. Neuroimage,2005,25(1):287-93.
[26] Groschel K, Hauser TK, Luft A, et al. Magnetic resonance imaging-based volumetrydifferentiates progressive supranuclear palsy from corticobasal degeneration[J].Neuroimage,2004,21(2):714-24.
[27] Wright IC, McGuire PK, Poline JB, et al. A voxel-based method for the statisticalanalysis of gray and white matter density applied to schizophrenia[J]. Neuroimage,1995,2(4):244-52.
[28] Ashburner J,Friston KJ. Voxel-based morphometry--the methods[J]. Neuroimage,2000,11(6Pt1):805-21.
[29] Brenneis C, Seppi K, Schocke MF, et al. Voxel-based morphometry detects corticalatrophy in the Parkinson variant of multiple system atrophy[J]. Mov Disord,2003,18(10):1132-8.
[30] Brenneis C, Seppi K, Schocke M, et al. Voxel based morphometry reveals a distinctpattern of frontal atrophy in progressive supranuclear palsy[J]. J Neurol NeurosurgPsychiatry,2004,75(2):246-9.
[31] Padovani A, Borroni B, Brambati SM, et al. Diffusion tensor imaging and voxel basedmorphometry study in early progressive supranuclear palsy[J]. J Neurol NeurosurgPsychiatry,2006,77(4):457-63.
[32] Boxer AL, Geschwind MD, Belfor N, et al. Patterns of brain atrophy that differentiatecorticobasal degeneration syndrome from progressive supranuclear palsy[J]. ArchNeurol,2006,63(1):81-6.
[33] Focke NK, Helms G, Pantel PM, et al. Differentiation of typical and atypicalParkinson syndromes by quantitative MR imaging[J]. AJNR Am J Neuroradiol,2011,32(11):2087-92.
[34] Price S, Paviour D, Scahill R, et al. Voxel-based morphometry detects patterns ofatrophy that help differentiate progressive supranuclear palsy and Parkinson'sdisease[J]. Neuroimage,2004,23(2):663-9.
[35] Josephs KA, Whitwell JL, Dickson DW, et al. Voxel-based morphometry in autopsyproven PSP and CBD[J]. Neurobiol Aging,2008,29(2):280-9.
[36] Erbetta A, Mandelli ML, Savoiardo M, et al. Diffusion tensor imaging shows differenttopographic involvement of the thalamus in progressive supranuclear palsy andcorticobasal degeneration[J]. AJNR Am J Neuroradiol,2009,30(8):1482-7.
[37] Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements ofthe middle cerebellar peduncle differentiate the Parkinson variant of MSA fromParkinson's disease and progressive supranuclear palsy[J]. Brain,2006,129(Pt10):2679-87.
[38] Nicoletti G, Tonon C, Lodi R, et al. Apparent diffusion coefficient of the superiorcerebellar peduncle differentiates progressive supranuclear palsy from Parkinson'sdisease[J]. Mov Disord,2008,23(16):2370-6.
[39] Pellecchia MT, Barone P, Mollica C, et al. Diffusion-weighted imaging in multiplesystem atrophy: a comparison between clinical subtypes[J]. Mov Disord,2009,24(5):689-96.
[40] Paviour DC, Thornton JS, Lees AJ, et al. Diffusion-weighted magnetic resonanceimaging differentiates Parkinsonian variant of multiple-system atrophy fromprogressive supranuclear palsy[J]. Mov Disord,2007,22(1):68-74.
[41] Wang PS, Wu HM, Lin CP, et al. Use of diffusion tensor imaging to identifysimilarities and differences between cerebellar and Parkinsonism forms of multiplesystem atrophy[J]. Neuroradiology,2011,53(7):471-81.
[42] Fujimori J, Tatewaki Y, Shimizu H, et al.[Degeneration of ponto-cerebellar tractvisualized by diffusion tensor imaging in multiple system atrophy][J]. RinshoShinkeigaku,2011,51(4):271-4.
[43] Agosta F, Pievani M, Svetel M, et al. Diffusion tensor MRI contributes to differentiateRichardson's syndrome from PSP-parkinsonism[J]. Neurobiol Aging,2012,33(12):2817-26.
[44] Whitwell JL, Master AV, Avula R, et al. Clinical correlates of white matter tractdegeneration in progressive supranuclear palsy[J]. Arch Neurol,2011,68(6):753-60.
[45] Kvickstrom P, Eriksson B, van Westen D, et al. Selective frontal neurodegeneration ofthe inferior fronto-occipital fasciculus in progressive supranuclear palsy (PSP)demonstrated by diffusion tensor tractography[J]. BMC Neurol,2011,11:13.
[46]于春水,李坤成.弥散张量成像纤维跟踪技术的研究进展[J].中国医学影像技术,2004,20(3):3.
[47]李亚迪,董海波,谢国民, et al.基于纤维束空间统计分析多参数DTI在遗忘型轻度认知障碍的应用[J].放射学实践,2012,27(6)
[48] Knake S, Belke M, Menzler K, et al. In vivo demonstration of microstructural brainpathology in progressive supranuclear palsy: a DTI study using TBSS[J]. Mov Disord,2010,25(9):1232-8.
[49] Abe K, Terakawa H, Takanashi M, et al. Proton magnetic resonance spectroscopy ofpatients with parkinsonism[J]. Brain Res Bull,2000,52(6):589-95.
[50] Takado Y, Igarashi H, Terajima K, et al. Brainstem metabolites in multiple systematrophy of cerebellar type:3.0-T magnetic resonance spectroscopy study[J]. MovDisord,2011,26(7):1297-302.
[51] Aotsuka A, Shinotoh H,Hattori T.[Magnetic resonance spectroscopy in Parkinson'sdisease and multiple system atrophy][J]. Nihon Rinsho,1997,55(1):249-54.
[52] Federico F, Simone IL, Lucivero V, et al. Proton magnetic resonance spectroscopy inParkinson's disease and atypical parkinsonian disorders[J]. Mov Disord,1997,12(6):903-9.
[53] Guevara CA, Blain CR, Stahl D, et al. Quantitative magnetic resonance spectroscopicimaging in Parkinson's disease, progressive supranuclear palsy and multiple systematrophy[J]. Eur J Neurol,2010,17(9):1193-202.
[54] Terakawa H, Abe K, Watanabe Y, et al. Proton magnetic resonance spectroscopy (1HMRS) in patients with sporadic cerebellar degeneration[J]. J Neuroimaging,1999,9(2):72-7.
[55]陈德强,贺丹.磁敏感加权成像技术原理及临床应用进展[J].脑与神经疾病杂志,2009,17(2):3.
[56] Arabia G, Morelli M, Paglionico S, et al. An magnetic resonance imagingT2*-weighted sequence at short echo time to detect putaminal hypointensity inParkinsonisms[J]. Mov Disord,2010,25(16):2728-34.
[57] Han YH, Lee JH, Kang BM, et al. Topographical differences of brain iron depositionbetween progressive supranuclear palsy and parkinsonian variant multiple systematrophy[J]. J Neurol Sci,2012,
[58] Gupta D, Saini J, Kesavadas C, et al. Utility of susceptibility-weighted MRI indifferentiating Parkinson's disease and atypical parkinsonism[J]. Neuroradiology,2010,52(12):1087-94.
[59] Wang Y, Butros SR, Shuai X, et al. Different iron-deposition patterns of multiplesystem atrophy with predominant parkinsonism and idiopathetic Parkinson diseasesdemonstrated by phase-corrected susceptibility-weighted imaging[J]. AJNR Am JNeuroradiol,2012,33(2):266-73.
[60] Hanyu H, Inoue Y, Sakurai H, et al. Regional cerebral blood flow changes in patientswith idiopathic REM sleep behavior disorder[J]. Eur J Neurol,2011,18(5):784-8.
[61] Eckert T, Sailer M, Kaufmann J, et al. Differentiation of idiopathic Parkinson'sdisease, multiple system atrophy, progressive supranuclear palsy, and healthy controlsusing magnetization transfer imaging[J]. Neuroimage,2004,21(1):229-35.
[2] Lang AE,Lozano AM. Parkinson's disease. First of two parts[J]. N Engl J Med,1998,339(15):1044-53.
[3] Zhang ZX, Roman GC, Hong Z, et al. Parkinson's disease in China: prevalence inBeijing, Xian, and Shanghai[J]. Lancet,2005,365(9459):595-7.
[4]徐仁,吴成斯,易娟, et al.帕金森叠加综合征[J].国外医学（老年医学分册）,2007,28(6):4.
[5] Tison F, Yekhlef F, Chrysostome V, et al. Prevalence of multiple system atrophy[J].Lancet,2000,355(9202):495-6.
[6] Bjornsdottir A, Gudmundsson G, Blondal H, et al. Incidence and prevalence ofmultiple system atrophy: a nationwide study in Iceland[J]. J Neurol NeurosurgPsychiatry,2013,84(2):136-40.
[7] Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinicalphenotypes in pathologically proven progressive supranuclear palsy: Richardson'ssyndrome and PSP-parkinsonism[J]. Brain,2005,128(Pt6):1247-58.
[8] Barsottini OG, Felicio AC, Aquino CC, et al. Progressive supranuclear palsy: newconcepts[J]. Arq Neuropsiquiatr,2010,68(6):938-46.
[9] Schrag A, Ben-Shlomo Y,Quinn NP. Prevalence of progressive supranuclear palsyand multiple system atrophy: a cross-sectional study[J]. Lancet,1999,354(9192):1771-5.
[10] Nath U, Ben-Shlomo Y, Thomson RG, et al. The prevalence of progressivesupranuclear palsy (Steele-Richardson-Olszewski syndrome) in the UK[J]. Brain,2001,124(Pt7):1438-49.
[11] Seppi K. MRI for the differential diagnosis of neurodegenerative parkinsonism inclinical practice[J]. Parkinsonism Relat Disord,2007,13Suppl3: S400-5.
[12] Behnke S, Berg D, Naumann M, et al. Differentiation of Parkinson's disease andatypical parkinsonian syndromes by transcranial ultrasound[J]. J Neurol NeurosurgPsychiatry,2005,76(3):423-5.
[13] Berg D. Transcranial sonography in movement disorders. Conclusions[J]. Int RevNeurobiol,2010,90:287-9.
[1] Lantos PL. The definition of multiple system atrophy: a review of recentdevelopments[J]. J Neuropathol Exp Neurol,1998,57(12):1099-111.
[2] Gilman S, Wenning GK, Low PA, et al. Second consensus statement on thediagnosis of multiple system atrophy[J]. Neurology,2008,71(9):670-6.
[3] Iodice V, Lipp A, Ahlskog JE, et al. Autopsy confirmed multiple system atrophycases: Mayo experience and role of autonomic function tests[J]. J NeurolNeurosurg Psychiatry,2012,83(4):453-9.
[4] Stefanova N, Bucke P, Duerr S, et al. Multiple system atrophy: an update[J]. LancetNeurol,2009,8(12):1172-8.
[5] Williams DR,Lees AJ. How do patients with parkinsonism present? Aclinicopathological study[J]. Intern Med J,2009,39(1):7-12.
[6] Wenning GK, Tison F, Ben Shlomo Y, et al. Multiple system atrophy: a review of203pathologically proven cases[J]. Mov Disord,1997,12(2):133-47.
[7] Watanabe H, Saito Y, Terao S, et al. Progression and prognosis in multiple systematrophy: an analysis of230Japanese patients[J]. Brain,2002,125(Pt5):1070-83.
[8] Yabe I, Soma H, Takei A, et al. MSA-C is the predominant clinical phenotype ofMSA in Japan: analysis of142patients with probable MSA[J]. J Neurol Sci,2006,249(2):115-21.
[9] Ito T, Sakakibara R, Yasuda K, et al. Incomplete emptying and urinary retention inmultiple-system atrophy: when does it occur and how do we manage it?[J]. MovDisord,2006,21(6):816-23.
[10] Wenning GK, Granata R, Krismer F, et al. Orthostatic hypotension is differentiallyassociated with the cerebellar versus the parkinsonian variant of multiple systematrophy: a comparative study[J]. Cerebellum,2012,11(1):223-6.
[11] Wenning GK, Scherfler C, Granata R, et al. Time course of symptomatic orthostatichypotension and urinary incontinence in patients with postmortem confirmedparkinsonian syndromes: a clinicopathological study[J]. J Neurol NeurosurgPsychiatry,1999,67(5):620-3.
[12] Ozawa T, Paviour D, Quinn NP, et al. The spectrum of pathological involvement ofthe striatonigral and olivopontocerebellar systems in multiple system atrophy:clinicopathological correlations[J]. Brain,2004,127(Pt12):2657-71.
[13] Spaccavento S, Del Prete M, Loverre A, et al. Multiple system atrophy with earlycognitive deficits: A case report[J]. Neurocase,2012,
[14] Steele JC, Richardson JC,Olszewski J. Progressive Supranuclear Palsy. AHeterogeneous Degeneration Involving the Brain Stem, Basal Ganglia andCerebellum with Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia andDementia[J]. Arch Neurol,1964,10:333-59.
[15] Barsottini OG, Felicio AC, Aquino CC, et al. Progressive supranuclear palsy: newconcepts[J]. Arq Neuropsiquiatr,2010,68(6):938-46.
[16]詹霞,王远臣,隋秀梅.进行性核上性麻痹3例并文献复习[J].疑难病杂志,2006,5(4):2.
[17] Lubarsky M,Juncos JL. Progressive supranuclear palsy: a current review[J].Neurologist,2008,14(2):79-88.
[18] Dubois B, Slachevsky A, Pillon B, et al."Applause sign" helps to discriminate PSPfrom FTD and PD[J]. Neurology,2005,64(12):2132-3.
[19] Kertesz A,McMonagle P. Behavior and cognition in corticobasal degeneration andprogressive supranuclear palsy[J]. J Neurol Sci,2010,289(1-2):138-43.
[20] Soliveri P, Monza D, Paridi D, et al. Neuropsychological follow up in patients withParkinson's disease, striatonigral degeneration-type multisystem atrophy, andprogressive supranuclear palsy[J]. J Neurol Neurosurg Psychiatry,2000,69(3):313-8.
[1] Konagaya M, Sakai M, Matsuoka Y, et al. Pathological correlate of the slitlikechanges on MRI at the putaminal margin in multiple system atrophy[J]. J Neurol,1999,246(2):142-3.
[2] Matsusue E, Fujii S, Kanasaki Y, et al. Putaminal lesion in multiple system atrophy:postmortem MR-pathological correlations[J]. Neuroradiology,2008,50(7):559-67.
[3] Watanabe H, Ito M, Fukatsu H, et al. Putaminal magnetic resonance imagingfeatures at various magnetic field strengths in multiple system atrophy[J]. MovDisord,2010,25(12):1916-23.
[4] Tha KK, Terae S, Tsukahara A, et al. Hyperintense putaminal rim at1.5T:prevalence in normal subjects and distinguishing features from multiple systematrophy[J]. BMC Neurol,2012,12:39.
[5] Savoiardo M, Strada L, Girotti F, et al. Olivopontocerebellar atrophy: MR diagnosisand relationship to multisystem atrophy[J]. Radiology,1990,174(3Pt1):693-6.
[6] Yokoyama T, Hasegawa K, Horiuchi E, et al. Multiple system atrophy (MSA) withmassive macrophage infiltration in the ponto-cerebellar afferent system[J].Neuropathology,2007,27(4):375-7.
[7] Cordato NJ, Duggins AJ, Halliday GM, et al. Clinical deficits correlate withregional cerebral atrophy in progressive supranuclear palsy[J]. Brain,2005,128(Pt6):1259-66.
[8] Schofield EC, Hodges JR, Macdonald V, et al. Cortical atrophy differentiatesRichardson's syndrome from the parkinsonian form of progressive supranuclearpalsy[J]. Mov Disord,2011,26(2):256-63.
[9] Morelli M, Arabia G, Novellino F, et al. MRI measurements predict PSP inunclassifiable parkinsonisms: a cohort study[J]. Neurology,2011,77(11):1042-7.
[10] Morelli M, Arabia G, Salsone M, et al. Accuracy of magnetic resonanceparkinsonism index for differentiation of progressive supranuclear palsy fromprobable or possible Parkinson disease[J]. Mov Disord,2011,26(3):527-33.
[1] Berg D. Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease:yes[J]. J Neural Transm,2011,118(4):613-9.
[2] Bartova P, Skoloudik D, Bar M, et al. Transcranial sonography in movementdisorders[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub,2008,152(2):251-8.
[3] Berg D. In vivo detection of iron and neuromelanin by transcranial sonography--anew approach for early detection of substantia nigra damage[J]. J Neural Transm,2006,113(6):775-80.
[4] Walter U. Transcranial sonography in brain disorders with trace metal accumulation[J].Int Rev Neurobiol,2010,90:166-78.
[5] Behnke S, Berg D, Naumann M, et al. Differentiation of Parkinson's disease andatypical parkinsonian syndromes by transcranial ultrasound[J]. J Neurol NeurosurgPsychiatry,2005,76(3):423-5.
[6] Gaenslen A, Unmuth B, Godau J, et al. The specificity and sensitivity of transcranialultrasound in the differential diagnosis of Parkinson's disease: a prospective blindedstudy[J]. Lancet Neurol,2008,7(5):417-24.
[7] Walter U, Niehaus L, Probst T, et al. Brain parenchyma sonography discriminatesParkinson's disease and atypical parkinsonian syndromes[J]. Neurology,2003,60(1):74-7.
[8] Walter U, Dressler D, Wolters A, et al. Sonographic discrimination of corticobasaldegeneration vs progressive supranuclear palsy[J]. Neurology,2004,63(3):504-9.
[9] Walter U, Dressler D, Lindemann C, et al. Transcranial sonography findings inwelding-related Parkinsonism in comparison to Parkinson's disease[J]. Mov Disord,2008,23(1):141-5.
[1] Graham JG,Oppenheimer DR. Orthostatic hypotension and nicotine sensitivity in acase of multiple system atrophy[J]. J Neurol Neurosurg Psychiatry,1969,32(1):28-34.
[2] Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosisof multiple system atrophy[J]. Neurology,2008,71(9):670-6.
[3] Steele JC, Richardson JC,Olszewski J. Progressive Supranuclear Palsy. AHeterogeneous Degeneration Involving the Brain Stem, Basal Ganglia andCerebellum with Vertical Gaze and Pseudobulbar Palsy, Nuchal Dystonia andDementia[J]. Arch Neurol,1964,10:333-59.
[4] Schrag A, Ben-Shlomo Y,Quinn NP. Prevalence of progressive supranuclear palsy andmultiple system atrophy: a cross-sectional study[J]. Lancet,1999,354(9192):1771-5.
[5] Barsottini OG, Felicio AC, Aquino CC, et al. Progressive supranuclear palsy: newconcepts[J]. Arq Neuropsiquiatr,2010,68(6):938-46.
[6] Ito S, Shirai W,Hattori T. Putaminal hyperintensity on T1-weighted MR imaging inpatients with the Parkinson variant of multiple system atrophy[J]. AJNR Am JNeuroradiol,2009,30(4):689-92.
[7] Matsusue E, Fujii S, Kanasaki Y, et al. Putaminal lesion in multiple system atrophy:postmortem MR-pathological correlations[J]. Neuroradiology,2008,50(7):559-67.
[8] Tha KK, Terae S, Tsukahara A, et al. Hyperintense putaminal rim at1.5T: prevalencein normal subjects and distinguishing features from multiple system atrophy[J]. BMCNeurol,2012,12:39.
[9] Sakurai K, Yamawaki T, Okita K, et al. Utility of the fluid-attenuated inversionrecovery sequence in detecting a hyperintense putaminal rim in multiple systematrophy-parkinsonism: a preliminary study[J]. Eur Neurol,2011,66(1):42-6.
[10] Watanabe H, Ito M, Fukatsu H, et al. Putaminal magnetic resonance imaging featuresat various magnetic field strengths in multiple system atrophy[J]. Mov Disord,2010,25(12):1916-23.
[11] Savoiardo M, Strada L, Girotti F, et al. Olivopontocerebellar atrophy: MR diagnosisand relationship to multisystem atrophy[J]. Radiology,1990,174(3Pt1):693-6.
[12] Massey LA, Micallef C, Paviour DC, et al. Conventional magnetic resonance imagingin confirmed progressive supranuclear palsy and multiple system atrophy[J]. MovDisord,2012,
[13] Ngai S, Tang YM, Du L, et al. Hyperintensity of the middle cerebellar peduncles onfluid-attenuated inversion recovery imaging: variation with age and implications forthe diagnosis of multiple system atrophy[J]. AJNR Am J Neuroradiol,2006,27(10):2146-8.
[14] Okamoto K, Tokiguchi S, Furusawa T, et al. MR features of diseases involvingbilateral middle cerebellar peduncles[J]. AJNR Am J Neuroradiol,2003,24(10):1946-54.
[15] Kataoka H, Tonomura Y, Taoka T, et al. Signal changes of superior cerebellarpeduncle on fluid-attenuated inversion recovery in progressive supranuclear palsy[J].Parkinsonism Relat Disord,2008,14(1):63-5.
[16] Righini A, Antonini A, De Notaris R, et al. MR imaging of the superior profile of themidbrain: differential diagnosis between progressive supranuclear palsy andParkinson disease[J]. AJNR Am J Neuroradiol,2004,25(6):927-32.
[17] Kato N, Arai K,Hattori T. Study of the rostral midbrain atrophy in progressivesupranuclear palsy[J]. J Neurol Sci,2003,210(1-2):57-60.
[18] Adachi M, Kawanami T, Ohshima H, et al. Morning glory sign: a particular MRfinding in progressive supranuclear palsy[J]. Magn Reson Med Sci,2004,3(3):125-32.
[19] Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation ofprogressive supranuclear palsy from Parkinson disease and the Parkinson variant ofmultiple system atrophy[J]. Radiology,2008,246(1):214-21.
[20] Gama RL, Tavora DF, Bomfim RC, et al. Morphometry MRI in the differentialdiagnosis of parkinsonian syndromes[J]. Arq Neuropsiquiatr,2010,68(3):333-8.
[21] Schrag A, Good CD, Miszkiel K, et al. Differentiation of atypical parkinsoniansyndromes with routine MRI[J]. Neurology,2000,54(3):697-702.
[22] Oba H, Yagishita A, Terada H, et al. New and reliable MRI diagnosis for progressivesupranuclear palsy[J]. Neurology,2005,64(12):2050-5.
[23] Morelli M, Arabia G, Salsone M, et al. Accuracy of magnetic resonance parkinsonismindex for differentiation of progressive supranuclear palsy from probable or possibleParkinson disease[J]. Mov Disord,2011,26(3):527-33.
[24] Schulz JB, Skalej M, Wedekind D, et al. Magnetic resonance imaging-basedvolumetry differentiates idiopathic Parkinson's syndrome from multiple systematrophy and progressive supranuclear palsy[J]. Ann Neurol,1999,45(1):65-74.
[25] Specht K, Minnerop M, Muller-Hubenthal J, et al. Voxel-based analysis ofmultiple-system atrophy of cerebellar type: complementary results by combiningvoxel-based morphometry and voxel-based relaxometry[J]. Neuroimage,2005,25(1):287-93.
[26] Groschel K, Hauser TK, Luft A, et al. Magnetic resonance imaging-based volumetrydifferentiates progressive supranuclear palsy from corticobasal degeneration[J].Neuroimage,2004,21(2):714-24.
[27] Wright IC, McGuire PK, Poline JB, et al. A voxel-based method for the statisticalanalysis of gray and white matter density applied to schizophrenia[J]. Neuroimage,1995,2(4):244-52.
[28] Ashburner J,Friston KJ. Voxel-based morphometry--the methods[J]. Neuroimage,2000,11(6Pt1):805-21.
[29] Brenneis C, Seppi K, Schocke MF, et al. Voxel-based morphometry detects corticalatrophy in the Parkinson variant of multiple system atrophy[J]. Mov Disord,2003,18(10):1132-8.
[30] Brenneis C, Seppi K, Schocke M, et al. Voxel based morphometry reveals a distinctpattern of frontal atrophy in progressive supranuclear palsy[J]. J Neurol NeurosurgPsychiatry,2004,75(2):246-9.
[31] Padovani A, Borroni B, Brambati SM, et al. Diffusion tensor imaging and voxel basedmorphometry study in early progressive supranuclear palsy[J]. J Neurol NeurosurgPsychiatry,2006,77(4):457-63.
[32] Boxer AL, Geschwind MD, Belfor N, et al. Patterns of brain atrophy that differentiatecorticobasal degeneration syndrome from progressive supranuclear palsy[J]. ArchNeurol,2006,63(1):81-6.
[33] Focke NK, Helms G, Pantel PM, et al. Differentiation of typical and atypicalParkinson syndromes by quantitative MR imaging[J]. AJNR Am J Neuroradiol,2011,32(11):2087-92.
[34] Price S, Paviour D, Scahill R, et al. Voxel-based morphometry detects patterns ofatrophy that help differentiate progressive supranuclear palsy and Parkinson'sdisease[J]. Neuroimage,2004,23(2):663-9.
[35] Josephs KA, Whitwell JL, Dickson DW, et al. Voxel-based morphometry in autopsyproven PSP and CBD[J]. Neurobiol Aging,2008,29(2):280-9.
[36] Erbetta A, Mandelli ML, Savoiardo M, et al. Diffusion tensor imaging shows differenttopographic involvement of the thalamus in progressive supranuclear palsy andcorticobasal degeneration[J]. AJNR Am J Neuroradiol,2009,30(8):1482-7.
[37] Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements ofthe middle cerebellar peduncle differentiate the Parkinson variant of MSA fromParkinson's disease and progressive supranuclear palsy[J]. Brain,2006,129(Pt10):2679-87.
[38] Nicoletti G, Tonon C, Lodi R, et al. Apparent diffusion coefficient of the superiorcerebellar peduncle differentiates progressive supranuclear palsy from Parkinson'sdisease[J]. Mov Disord,2008,23(16):2370-6.
[39] Pellecchia MT, Barone P, Mollica C, et al. Diffusion-weighted imaging in multiplesystem atrophy: a comparison between clinical subtypes[J]. Mov Disord,2009,24(5):689-96.
[40] Paviour DC, Thornton JS, Lees AJ, et al. Diffusion-weighted magnetic resonanceimaging differentiates Parkinsonian variant of multiple-system atrophy fromprogressive supranuclear palsy[J]. Mov Disord,2007,22(1):68-74.
[41] Wang PS, Wu HM, Lin CP, et al. Use of diffusion tensor imaging to identifysimilarities and differences between cerebellar and Parkinsonism forms of multiplesystem atrophy[J]. Neuroradiology,2011,53(7):471-81.
[42] Fujimori J, Tatewaki Y, Shimizu H, et al.[Degeneration of ponto-cerebellar tractvisualized by diffusion tensor imaging in multiple system atrophy][J]. RinshoShinkeigaku,2011,51(4):271-4.
[43] Agosta F, Pievani M, Svetel M, et al. Diffusion tensor MRI contributes to differentiateRichardson's syndrome from PSP-parkinsonism[J]. Neurobiol Aging,2012,33(12):2817-26.
[44] Whitwell JL, Master AV, Avula R, et al. Clinical correlates of white matter tractdegeneration in progressive supranuclear palsy[J]. Arch Neurol,2011,68(6):753-60.
[45] Kvickstrom P, Eriksson B, van Westen D, et al. Selective frontal neurodegeneration ofthe inferior fronto-occipital fasciculus in progressive supranuclear palsy (PSP)demonstrated by diffusion tensor tractography[J]. BMC Neurol,2011,11:13.
[46]于春水,李坤成.弥散张量成像纤维跟踪技术的研究进展[J].中国医学影像技术,2004,20(3):3.
[47]李亚迪,董海波,谢国民, et al.基于纤维束空间统计分析多参数DTI在遗忘型轻度认知障碍的应用[J].放射学实践,2012,27(6)
[48] Knake S, Belke M, Menzler K, et al. In vivo demonstration of microstructural brainpathology in progressive supranuclear palsy: a DTI study using TBSS[J]. Mov Disord,2010,25(9):1232-8.
[49] Abe K, Terakawa H, Takanashi M, et al. Proton magnetic resonance spectroscopy ofpatients with parkinsonism[J]. Brain Res Bull,2000,52(6):589-95.
[50] Takado Y, Igarashi H, Terajima K, et al. Brainstem metabolites in multiple systematrophy of cerebellar type:3.0-T magnetic resonance spectroscopy study[J]. MovDisord,2011,26(7):1297-302.
[51] Aotsuka A, Shinotoh H,Hattori T.[Magnetic resonance spectroscopy in Parkinson'sdisease and multiple system atrophy][J]. Nihon Rinsho,1997,55(1):249-54.
[52] Federico F, Simone IL, Lucivero V, et al. Proton magnetic resonance spectroscopy inParkinson's disease and atypical parkinsonian disorders[J]. Mov Disord,1997,12(6):903-9.
[53] Guevara CA, Blain CR, Stahl D, et al. Quantitative magnetic resonance spectroscopicimaging in Parkinson's disease, progressive supranuclear palsy and multiple systematrophy[J]. Eur J Neurol,2010,17(9):1193-202.
[54] Terakawa H, Abe K, Watanabe Y, et al. Proton magnetic resonance spectroscopy (1HMRS) in patients with sporadic cerebellar degeneration[J]. J Neuroimaging,1999,9(2):72-7.
[55]陈德强,贺丹.磁敏感加权成像技术原理及临床应用进展[J].脑与神经疾病杂志,2009,17(2):3.
[56] Arabia G, Morelli M, Paglionico S, et al. An magnetic resonance imagingT2*-weighted sequence at short echo time to detect putaminal hypointensity inParkinsonisms[J]. Mov Disord,2010,25(16):2728-34.
[57] Han YH, Lee JH, Kang BM, et al. Topographical differences of brain iron depositionbetween progressive supranuclear palsy and parkinsonian variant multiple systematrophy[J]. J Neurol Sci,2012,
[58] Gupta D, Saini J, Kesavadas C, et al. Utility of susceptibility-weighted MRI indifferentiating Parkinson's disease and atypical parkinsonism[J]. Neuroradiology,2010,52(12):1087-94.
[59] Wang Y, Butros SR, Shuai X, et al. Different iron-deposition patterns of multiplesystem atrophy with predominant parkinsonism and idiopathetic Parkinson diseasesdemonstrated by phase-corrected susceptibility-weighted imaging[J]. AJNR Am JNeuroradiol,2012,33(2):266-73.
[60] Hanyu H, Inoue Y, Sakurai H, et al. Regional cerebral blood flow changes in patientswith idiopathic REM sleep behavior disorder[J]. Eur J Neurol,2011,18(5):784-8.
[61] Eckert T, Sailer M, Kaufmann J, et al. Differentiation of idiopathic Parkinson'sdisease, multiple system atrophy, progressive supranuclear palsy, and healthy controlsusing magnetization transfer imaging[J]. Neuroimage,2004,21(1):229-35.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |